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Teresa Bastante, MD, Fernando Rivero, MD, Amparo Benedicto, MD, Javier Cuesta, MD, Fernando Alfonso, MD, PHDA 66-year-old manpresentedanon–ST-segmentelevation myocardial infarction 3 yearsafter the implantation of an everolimus-
eluting stent (3.5  12 mm) in the proximal segment
of a saphenous vein graft to a marginal branch. Coro-
nary angiography showed focal in-stent restenosis
(ISR) and optical coherence tomography (OCT)
conﬁrmed severe ISR (minimal lumen area 3.1 mm2).
Notably, the tissue causing ISR had a strikingFIGURE 1 OCT Findings in Serial Studies
(A and A0) In-stent restenosis caused by neoatherosclerosis pre-interven
geneous tissue mainly consisting of large lipid areas (plus signs) that pa
shadow). (B and B0) Results obtained immediately after bioresorbable v
without shadowing. There is minor protrusion of some lipid tissue (plus s
pools (plus signs) are detected within the BVS struts. The asterisk deno
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tima covering large lipid pools (plus signs,
Figures 1A and 1A0) that obscured the underlying
stent struts, highly suggestive of neoatherosclerosis.
A bioresorbable vascular scaffold (BVS) (Absorb, 3.5 
12 mm) was implanted and post-dilated at very
high pressure (22 bar) with excellent angiographic
and OCT results (minimal lumen area 8.5 mm2)
(Figures 1B and 1B0). The classic “black box” BVStion. A glistening yellow neointima is visualized covering a hetero-
rtially obscure the underlying metallic struts (bright dots with dorsal
ascular scaffold (BVS) implantation. BVS struts appear as black boxes
igns). (C and C0) Recurrent neoatherosclerosis at follow-up. New lipid
tes the wire artifact. OCT ¼ optical coherence tomography.
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1265appearance (without shadowing) was readily identi-
ﬁed fully apposed against residual tissue overlying
the bright artefacts (with dorsal shadow) of the under-
lying metallic struts (Figures 1B and 1B0). Seven months
later, the patient presented with another non–ST-
segment elevation myocardial infarction showing
recurrent ISR on angiography. OCT disclosed that the
obstructive tissue (minimal lumen area 3.3 mm2)
was consistent with recurrent neoatherosclerosis
(Figures 1C and 1C0). A drug-eluting stent was implanted
at high pressure with excellent ﬁnal result.
Treatment of patients with neoatherosclerosis
remains a challenge (1,2). Recently, BVS have beenproposed as an attractive therapeutic strategy for
patients with ISR in order to avoid the implantation
of another permanent metal layer (3). To our knowl-
edge, this is the ﬁrst report of recurrent ISR following
treatment of ISR with BVS. Our ﬁndings also suggest
that recurrent neoatherosclerosis may develop after
BVS implantation in this challenging scenario.
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